Where: China, Brazil and India
Deal Size: $120 million
Details: A year before Amgen won approval of denosumab for postmenopausal women with osteoporosis, GlaxoSmithKline snagged marketing rights for the drug in China, Brazil and India--three of the largest emerging pharmaceutical markets. Additionally, GSK got rights to sell the drug in South Korea and all other markets where Amgen doesn't have a commercial presence.
Amgen and GSK also agreed to share commercialization of denosumab in Europe, Australia, New Zealand and Mexico. The Big Biotech got an initial payment and near-term commercial milestones to Amgen totaling $120 million, and ongoing royalties. Analysts estimate the drug could eventually reach up to $2 billion in annual sales.